Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the
stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates ( 131 I, 88/…

111 In-Diethylenetriaminepentaacetic acid-octreotide generally is used for the scintigraphic
imaging of neuroendocrine and other somatostatin receptor–positive tumors. On the basis of …

In most types of peptide receptor radionuclide therapy, the maximum activity dose that can
be administered is limited by high and persistent renal retention of the radiolabeled peptides, …

Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT)
candidates to confirm tumor targeting and to estimate radiation doses to tumor and normal tissues…

Several radiolabeled chemotactic peptides have been tested for their suitability to show
infection and inflammation. Leukotriene B 4 (LTB 4 ) receptor-binding ligands could be useful …

Introduction: With the introduction of positron-emitting radionuclides with half-lifes in days,
such as 89 Zr and 124 I, radioimmunoscintigraphy (RIS) with positron-emitter-labeled …

Background Treatment of patients with peritoneal carcinomatosis (PC) of colorectal cancer (CRC)
includes cytoreductive surgery (CS) in combination with (hyperthermic) intraperitoneal …

Radiolabeled chemotactic peptides have been studied for their applicability to the
visualization of infectious and inflammatory foci. Because a radiolabeled leukotriene B4 (LTB4) …

Radiolabeled leukotriene B4 (LTB4) antagonist DPC11870 is able to reveal infectious and
inflammatory foci in distinct animal models. Because previous studies showed that …

Studies have demonstrated that the bivalent 111 In-labeled leukotriene B4 (LTB4) antagonist
DPC11870 reveals infectious and inflammatory lesions in various rabbit models. The …